journal
Journals Recent Patents on CNS Drug Dis...

Recent Patents on CNS Drug Discovery

https://read.qxmd.com/read/24605940/migraine-attack-treatment-a-tailor-made-suit-not-one-size-fits-all
#21
REVIEW
Robert Belvis, Natalia Mas, Azahara Aceituno
About 15% of people in the world suffer migraine attacks. Migraine can induce a great impact in the quality of life, and the costs of medical care and loss of productivity can be also high. Non-steroidal anti-inflammatory drugs (NSAIDs) are the best treatment in mild-to-moderate migraine attacks and triptans are the first line option in the acute treatment of moderate-to-severe migraine attacks. At present, there are seven marketed triptans: sumatriptan, rizatriptan, zolmitriptan, eletriptan, naratriptan, almotriptan and frovatriptan...
April 2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/24605939/therapeutic-potential-of-cannabinoids-in-schizophrenia
#22
REVIEW
Jana Kucerova, Katarina Tabiova, Filippo Drago, Vincenzo Micale
Increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. The endocannabinoid system comprises of two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle Δ(9)-tetrahydrocannabinol), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. It has been suggested to be a pro-homeostatic and pleiotropic signalling system activated in a time- and tissue-specific manner during pathophysiological conditions...
April 2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/24483711/recent-advances-in-the-treatment-of-neurogenic-erectile-dysfunction
#23
REVIEW
Rocco S Calabro, Giovanni Polimeni, Placido Bramanti
Neurogenic erectile dysfunction (ED) can be broadly defined as an inability to sustain or maintain a penile erection owing to a neurological impairment, either centrally or peripherally or both. Although significant advances in the pharmacological treatment of ED have occurred in recent years, especially after the introduction of oral selective phosphodiesterase type 5 inhibitor, the treatment of neurological patients with ED may be challenging for prescribers, given poor data available on this topic and the variety of etiologic factors (iatrogenic, endocrine, psychiatric and psychosocial) to consider...
April 2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/25666180/genetic-and-bioinformatic-studies-of-antidepressant-drug-therapeutic-efficacy-and-toxicity-a-current-overview
#24
REVIEW
Da-Yong Lu, Ting-Ren Lu, Jin-Yu Che, Peng-Peng Zhu
Antidepressants can relief human depression and reduce human depressive symptoms. Nevertheless, some undesired clinical events, such as suicide have been emerging. As for 2004, the US and European regulatory agencies began implementing verification programs to assess the influence on suicidal behavior from the use of antidepressants such as selective serotonin reuptake inhibitors (SSRIs). With the increasing number of reported cases, several newly developed antidepressants were faced with withdrawal from the markets...
2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/25643127/treatment-of-chronic-migraine-with-intramuscular-pericranial-injections-of-onabotulinumtoxin-a
#25
RANDOMIZED CONTROLLED TRIAL
Robert Belvis, Natalia Mas
Chronic migraine is the most frequent and disabling complication of migraine. To date, only two drugs have been specifically analysed for the treatment of chronic migraine, topiramate and onabotulinumtoxin A, and in the evidence-based medicine categories, they have achieved level of evidence I and as such, a grade of recommendation A according to current guidelines. Following the PREEMPT paradigm, pericranial intramuscular onabotulinumtoxin A injections show a good efficacy and safety in chronic migraine patients, both in phase III randomized clinical trials and in a pooled data analyses...
2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/25643126/pathophysiology-and-treatment-of-nonfamilial-hyperparathyroidism
#26
REVIEW
Franco Lumachi, Stefano M M Basso
Primary hyperparathyroidism (HPT) is the main cause of hypercalcemia and the most common parathyroid glands disease. The diagnosis is easy in patients with hypercalcemia and elevated PTH serum level. Minimally invasive parathyroidectomy (PTx) represents the treatment of choice for symptomatic patients, leading to several advantages, including immediate normalization of hypercalcemia and significant improvement of bone mineral density, cardiovascular dysfunctions, neuropsychological symptoms and quality of life...
2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/25537484/liver-growth-factor-as-a-tissue-regenerating-factor-in-neurodegenerative-diseases
#27
REVIEW
Rafael Gonzalo-Gobernado, Lucia Calatrava-Ferreras, Juan Perucho, Diana Reimers, MarIa J Casarejos, Antonio S Herranz, Adriano Jimenez-Escrig, Juan J Diaz-Gil, Eulalia Bazan
Liver growth factor (LGF) is a hepatic mitogen purified by our group in 1986. In the following years we demonstrated its activity both in "in vivo" and "in vitro" systems, stimulating hepatocytes mitogenesis as well as liver regeneration in several models of liver injury. Furthermore, we established its chemical composition (albumin-bilirubin complex) and its mitogenic actions in liver. From 2000 onwards we used LGF as a tissue regenerating factor in several models of extrahepatic diseases. The use of Liver growth factor as a neural tissue regenerator has been recently protected (Patent No US 2014/8,642,551 B2)...
2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/25429704/drug-drug-interactions-antiretroviral-drugs-and-recreational-drugs
#28
REVIEW
Orietta Staltari, Christian Leporini, Benedetto Caroleo, Emilio Russo, Antonio Siniscalchi, Giovambattista De Sarro, Luca Gallelli
With the advances in antiretroviral (ARV) therapy, patients with Human Immunodeficiency Virus (HIV) infection are living longer, however, some patients encounter co- morbidities which sometimes require treatment. Therefore, during the treatment with ARV drugs these patients could take several recreational drugs (e.g. amphetamines, hallucinogenes, opiates, or alcohol) with a possible development of drug-drug interactions (DDIs). In particular, Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) are mainly excreted through the kidney and are not substrates of the cytochrome P450 or P-glycoprotein, therefore the DDIs during this treatment are minimal...
2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/25413004/pharmacological-approaches-to-targeting-muscarinic-acetylcholine-receptors
#29
REVIEW
Carlo Matera, Ada M Tata
The presence of cholinergic system markers and muscarinic receptor subtypes in several tissues also of nonneuronal type has been largely demonstrated. Acetylcholine, synthesized in the nervous system, can locally contribute to modulate cell proliferation, survival and apoptosis. Considering that the cholinergic system functions are impaired in a number of disorders, the identification of new drugs regulating these functions appears of great clinical relevance. The possible involvement of muscarinic acetylcholine receptors in different pathologies has been proposed in recent years and is becoming an important area of study...
2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/25386917/possible-physiopathological-effects-of-the-transglutaminase-activity-on-the-molecular-mechanisms-responsible-for-human-neurodegenerative-diseases
#30
REVIEW
Martina Iannaccone, Federica Titta, Enrica Serretiello, Marco Monfregola, Vittorio Gentile
Transglutaminases are a class of ubiquitous enzymes which catalyze post-translational modifications of proteins. The main activity of these enzymes is the cross-linking of glutaminyl residues of a protein/peptide substrate to lysyl residues of a protein/peptide co-substrate. In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or polyamines (to form mono- or bi-substituted /crosslinked adducts) or -OH groups (to form ester linkages). In absence of co-substrates, the nucleophile may be water, resulting in the net deamidation of the glutaminyl residue...
2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/25386916/advancing-drug-therapy-for-brain-tumours-a-current-review-of-the-pro-inflammatory-peptide-substance-p-and-its-antagonists-as-anti-cancer-agents
#31
REVIEW
Kimberley Mander, Elizabeth Harford-Wright, Kate M Lewis, Robert Vink
Evidence for the involvement of the Substance P (SP)/NK1 receptor system in the development and progression of cancer strongly supports its potential as a therapeutic target in malignancies. Novel strategies for approaching cancer treatment are urgently required particularly with regard to tumours of the central nervous system (CNS), which are notoriously difficult to effectively treat and associated with extremely poor prognosis for many patients. This is due, in part, to the presence of the highly specialised blood-brain barrier, which is known to restrict common treatments such as chemotherapy and hinder early tumour diagnosis...
2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/25244580/patents-on-potential-drugs-to-treat-alzheimer-s-disease-special-emphasis-on-small-peptides
#32
REVIEW
Pazhani Sundaram, Aravind K Nambiar, Ranjini K Sundaram
The primary objective of this article is to review patents and the related scientific work on naturally occurring compounds, heterocyclic compounds and small peptides that are being explored for their utility for the treatment of Alzheimer's disease (AD). In this review, a special emphasis is given to the patents, including our patent issued in 2013, on peptides that bind to A. Utility of the peptides that prevent aggregation or those that help in clearance of Aβ is discussed as the latter can be considered as an important arm in combination therapy for AD...
2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/24924102/possible-physiopathological-roles-of-the-transglutaminase-activity-in-the-etiopathogenesis-of-human-neurodegenerative-diseases
#33
REVIEW
Federica Titta, Martina Iannaccone, Antonio Martin, Vittorio Gentile
Transglutaminases are ubiquitous enzymes which catalyze post-translational modifications of proteins. The main activity of these enzymes is the cross-linking of glutaminyl residues of a protein/peptide substrate to lysyl residues of a protein/peptide co-substrate. In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or polyamines (to form mono- or bi-substituted /crosslinked adducts) or -OH groups (to form ester linkages). In the absence of co-substrates, the nucleophile may be water, resulting in the net deamidation of the glutaminyl residue...
2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/24924101/recent-patents-on-novel-mch1-receptor-antagonists-as-potential-anti-obesity-drugs
#34
JOURNAL ARTICLE
Katalin K Szalai, Gyula Beke, János Éles, Tamás Kitka, Péter Kovács, József Nagy, Sándor Farkas, András Boros
Today, the 'obesity pandemic' is one of the biggest health issues around the world. Melanin-concentrating hormone (MCH), a hypothalamic neuropeptide, is one of the most potent, central stimulators of feeding and it also attenuates energy expenditure. Inhibitions of the MCH receptor, the melanin-concentrating hormone receptor-1 (MCHR1), has attracted considerable attention as a potential anti-obesity drug, during the last decade. Now, there are a large number of MCHR1 antagonists, pharmacological tools and clinical drug candidates that can provide clues to develop new structures with high potency and good pharmacokinetic profile...
2014: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/24330124/cerebrovascular-ultrasonography-for-selecting-patients-for-stroke-intervention
#35
REVIEW
Vijay K Sharma, Kusuma Yohanna, Ghulam Kawnayn, Nabin Sarkar, Amit Batra
Currently employed diagnostic ultrasonography provides clinically relevant information about cerebral hemodynamic changes in patients with cerebrovascular ischemia. The information thus obtained is often helpful to the physician for establishing or confirming the diagnosis and prognosis as well as in taking appropriate therapeutic decisions. It is associated with a high temporal resolution and can be performed bedside for rapid diagnosis as well as prolonged monitoring. Transcranial Doppler (TCD) ultrasonography is a non-invasive diagnostic modality that provides physiological information regarding various intracranial hemodynamic alterations in patients with cerebrovascular ischemia...
December 2013: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/24330123/modulation-of-the-trpv1-channel-current-clinical-trials-and-recent-patents-with-focus-on-neurological-conditions
#36
REVIEW
Luciano De Petrocellis, Aniello S Moriello
The transient receptor potential vanilloid-1 cat ion channel (TRPV1) is a nonspecific cation channel that can be activated by multiple endogenous stimuli and is expressed predominantly in sensory neurons, where it serves as a key nodal point in pain transmission pathways. In mammals, TRPV1 displays a wide tissue and cellular expression including both the peripheral and central nervous system, and in the latter it is now recognized to have a broader distribution and function. The pharmacological modulation of TRPV1 represents a strategy for the treatment of a variety of disease states, particularly those requiring chronic pain management...
December 2013: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/24286450/patents-on-brain-permeable-nanoparticles
#37
REVIEW
Monica Gulati, Dimple S Chopra, Sachin K Singh, Vikrant Saluja, Purnima Pathak, Parikshit Bansal
The blood-brain barrier (BBB) presents a combination of physical and electrostatic barriers. It is a highly complex structure that tightly regulates the movement of molecules from the blood to brain, protecting it from injuries and diseases. However, the BBB also significantly precludes the delivery of drugs to the brain, thus, preventing the therapy of a number of neurological disorders like brain cancer, epilepsy, Alzheimer's disease, schizophrenia etc. Numerous drug delivery strategies have been developed to circumvent this barrier...
December 2013: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/24286449/transglutaminase-activity-as-a-possible-therapeutical-target-in-neurodegenerative-diseases
#38
REVIEW
Martina Iannaccone, Federica Titta, Enrica Serretiello, Giulia De Vivo, Antonio Martin, Vittorio Gentile
Transglutaminases are ubiquitous enzymes which catalyze post-translational modifications of proteins. The main activity of these enzymes is the cross-linking of glutaminyl residues of a protein/peptide substrate to lysyl residues of a protein/peptide co-substrate. In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or polyamines (to form mono- or bi-substituted /crosslinked adducts) or -OH groups (to form ester linkages). In absence of co-substrates, the nucleophile may be water, resulting in the net deamidation of the glutaminyl residue...
December 2013: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/24050250/an-ion-channel-chip-for-diagnosis-and-prognosis-of-autoimmune-neurological-disorders
#39
JOURNAL ARTICLE
Franck C Chatelain, Michel Mazzuca, Marie-Madeleine Larroque, Veronique Rogemond, Jerome Honnorat, Florian Lesage
Autoantibodies directed against ion channels and ionotropic receptors are associated with neuromuscular and neurological disorders. Their detection has proven to be useful for diagnosis, prognosis and treatment of these autoimmune syndromes. We have designed an ion channel chip for the systematic and rapid screening of antibodies directed against tens of different ion channels. The chip has been validated by confirming the presence of autoantibodies in patients with anti-NMDA receptor encephalitis. Such a chip will be useful for the diagnosis of already documented disorders, but also to identify new targets of autoimmunity and classification of the corresponding diseases...
December 2013: Recent Patents on CNS Drug Discovery
https://read.qxmd.com/read/23713989/the-role-of-cnidaria-in-drug-discovery-a-review-on-cns-implications-and-new-perspectives
#40
REVIEW
Gian Luigi Mariottini, Luigi Pane
Many organisms produce bioactive substances used in the production of drugs. In this context, Cnidaria occupy a major position; for this reason, research on new bioactive substances has focused upon them as an interesting target. As a matter of fact, substances and extracts able to fight human diseases have been found in cnidarians, several of which have been studied in laboratories using animal models or cell cultures and, at present, some are in the pre-clinical phase. This review aims to highlight the research on existing drugs or new drug candidates extracted from Cnidaria and the recent patents published in this field; furthermore, as many cnidarian venoms are known to have an impact on the CNS and on neuromuscular transmission, this review particularly considers the research concerning CNS drug discovery and pending patents...
August 2013: Recent Patents on CNS Drug Discovery
journal
journal
41274
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.